SCHEMBL8556930

SCHEMBL8556930

CCOC(C)OCCCBr

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2355488 0.91 LMNA (0.52) LMNATHRB
SCHEMBL11355413 0.91 LMNA (0.52) LMNATHRB
SCHEMBL4599059 0.85
SCHEMBL1426655 0.80 LMNA (0.63) LMNATHRB
SCHEMBL3453066 0.79
SCHEMBL10004751 0.78 LMNA (0.60) LMNATHRB
SCHEMBL2810081 0.78
SCHEMBL9193325 0.77 LMNA (0.52) LMNATHRB
SCHEMBL14982598 0.76 LMNA (0.57) LMNATHRB
SCHEMBL873415 0.76 LMNA (0.57) LMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS ALNYLAM PHARMACEUTICALS, INC. 2014-10-16 US disclosed
EP-0816362-A1 THIAZOLE DERIVATIVES TAISHO PHARMACEUTICAL CO. LTD (JP) 1998-01-07 EP disclosed
US-5191108-A Lipoxygenase inhibitors, antiinflammatory agents HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US disclosed
US-5075327-A Antipsoriatic agents HOFFMANN-LA ROCHE INC. (US) 1991-12-24 US disclosed
US-5047432-A Antidepressants THE BOOTS COMPANY PLC (GB) 1991-09-10 US disclosed
US-5025036-A Antiinflammatory agents, gastrointestinal, cardiovascular and skin disorders HOFFMANN-LA ROCHE INC. (US) 1991-06-18 US disclosed
CN-1012733-B Process for the preparation of therapeutic agents BOOTS CO PLC (GB) 1991-06-05 CN disclosed
US-4937373-A Substituted naphthalene carboxylic acids HOFFMANN-LA ROCHE INC. (US) 1990-06-26 US disclosed
US-4925879-A ANTIDEPRESSANTS BOOTS COMPANY, PLC (GB) 1990-05-15 US disclosed
EP-0191542-B1 ARYLCYCLOBUTYLALKYL AMINES AND THEIR USE AS ANTIDEPRESSIVE MEDICINES The Boots Company PLC (GB) 1988-06-08 EP disclosed
CN-86100954-A The preparation method of therapeutical agent and application 1986-09-03 CN disclosed
EP-0191542-A1 Arylcyclobutylalkyl amines and their use as antidepressive medicines The Boots Company PLC (GB) 1986-08-20 EP disclosed
US-4014946-A Synthesis of 1-bromonon-4-en-6-yne ZOECON CORPORATION (US) 1977-03-29 US disclosed
US-3994896-A Sulfonate esters of non-4-en-6-yn-1-ol ZOECON CORPORATION (US) 1976-11-30 US disclosed
US-3985813-A Unsaturated alcohols ZOECON CORPORATION (US) 1976-10-12 US disclosed
US-3954818-A Synthesis of non-4-en-6-ynoic acid ester ZOECON CORPORATION (US) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140308304-A1 LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS NPC1L1, NPC1, CETP LMNA 958/4885THRB 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.